Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 4
2006 2
2007 1
2008 1
2009 1
2010 1
2013 1
2014 3
2015 2
2016 3
2017 1
2019 1
2020 6
2021 6
2022 4
2023 3
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.
Buffoni M, Dalla Volta A, Valcamonico F, Bergamini M, Caramella I, D'Apollo D, Zivi A, Procopio G, Sepe P, Del Conte G, Di Meo N, Foti S, Zamboni S, Messina C, Lucchini E, Maroldi R, Laganà M, Ravanelli M, Zamparini M, Zacchi F, Suardi N, Farina D, Berruti A. Buffoni M, et al. Among authors: valcamonico f. Eur Urol Oncol. 2025 Jun;8(3):782-791. doi: 10.1016/j.euo.2025.02.006. Epub 2025 Apr 28. Eur Urol Oncol. 2025. PMID: 40300921 Free article. Clinical Trial.
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A. Bergamini M, et al. Among authors: valcamonico f. Elife. 2024 Apr 24;13:e92655. doi: 10.7554/eLife.92655. Elife. 2024. PMID: 38656229 Free PMC article. Clinical Trial.
Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients.
Dalla Volta A, Caramella I, Di Mauro P, Bergamini M, Cosentini D, Valcamonico F, Cappelli C, Laganà M, Di Meo N, Farina D, Pedersini R, Mazziotti G, Berruti A. Dalla Volta A, et al. Among authors: valcamonico f. Curr Oncol Rep. 2023 Oct;25(10):1141-1152. doi: 10.1007/s11912-023-01447-9. Epub 2023 Aug 25. Curr Oncol Rep. 2023. PMID: 37624550 Free PMC article. Review.
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Dalla Volta A, Valcamonico F, Zivi A, Procopio G, Sepe P, Del Conte G, Di Meo N, Foti S, Zamboni S, Messina C, Lucchini E, Rizzi A, Ravanelli M, Calza S, Zacchi F, Ciccone G, Suardi N, Maroldi R, Farina D, Berruti A. Dalla Volta A, et al. Among authors: valcamonico f. Prostate Cancer Prostatic Dis. 2025 May 3. doi: 10.1038/s41391-025-00975-8. Online ahead of print. Prostate Cancer Prostatic Dis. 2025. PMID: 40319177
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.
Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Prayer Galetti T, Garolla A, Giannatempo P, Guerra L, La Spina S, Malatino L, Marchiano' A, Monti M, Morbiato FF, Morelli F, Nole' F, Palazzi S, Procopio G, Rosti G, Sacco C, Salvetti A, Salvioni R, Sava T, Secondino S, Serpentini S, Spreafico C, Tavolini IM, Valcamonico F, Verri E, Zucali P, De Giorgi U. Banna GL, et al. Among authors: valcamonico f. Crit Rev Oncol Hematol. 2019 May;137:154-164. doi: 10.1016/j.critrevonc.2019.03.006. Epub 2019 Mar 20. Crit Rev Oncol Hematol. 2019. PMID: 31014511 Review.
Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?
Caramella I, Dalla Volta A, Valcamonico F, Grisanti S, Berruti A. Caramella I, et al. Among authors: valcamonico f. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):797. doi: 10.1038/s41391-021-00474-6. Epub 2021 Nov 22. Prostate Cancer Prostatic Dis. 2022. PMID: 34811500 No abstract available.
Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues.
Roca E, Valcamonico F, Amoroso V, Antonelli A, Foroni C, Simeone C, Berruti A. Roca E, et al. Among authors: valcamonico f. J Clin Oncol. 2016 Oct 20;34(30):3709-3710. doi: 10.1200/JCO.2016.68.2617. J Clin Oncol. 2016. PMID: 27458304 No abstract available.
41 results